vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $19.1M, roughly 1.6× NewAmsterdam Pharma Co N.V.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -90.7%, a 127.0% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 37.6%). Ponce Financial Group, Inc. produced more free cash flow last quarter ($54.6M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
NAMS vs PDLB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $31.4M |
| Net Profit | $-17.4M | $10.1M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | 43.6% |
| Net Margin | -90.7% | 36.3% |
| Revenue YoY | 740.1% | 37.6% |
| Net Profit YoY | 55.5% | 245.6% |
| EPS (diluted) | $-0.15 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $31.4M | ||
| Q3 25 | — | $26.7M | ||
| Q2 25 | $19.1M | $26.5M | ||
| Q1 25 | — | $24.6M | ||
| Q4 24 | $12.8M | $22.8M | ||
| Q3 24 | $29.1M | $20.2M | ||
| Q2 24 | — | $20.2M | ||
| Q1 24 | — | $20.5M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-17.4M | $6.1M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | $-92.2M | $2.9M | ||
| Q3 24 | $-16.6M | $2.4M | ||
| Q2 24 | — | $3.2M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | — | 43.6% | ||
| Q3 25 | — | 32.8% | ||
| Q2 25 | -186.1% | 30.2% | ||
| Q1 25 | — | 32.5% | ||
| Q4 24 | -338.5% | 19.6% | ||
| Q3 24 | -85.9% | 15.2% | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | 18.3% |
| Q4 25 | — | 36.3% | ||
| Q3 25 | — | 24.3% | ||
| Q2 25 | -90.7% | 23.0% | ||
| Q1 25 | — | 24.2% | ||
| Q4 24 | -721.7% | 14.1% | ||
| Q3 24 | -57.2% | 12.1% | ||
| Q2 24 | — | 15.8% | ||
| Q1 24 | — | 11.8% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | $-0.15 | $0.25 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | $-0.91 | $0.11 | ||
| Q3 24 | $-0.18 | $0.10 | ||
| Q2 24 | — | $0.14 | ||
| Q1 24 | — | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $126.2M |
| Total DebtLower is stronger | — | $596.1M |
| Stockholders' EquityBook value | $778.5M | $541.5M |
| Total Assets | $815.1M | $3.2B |
| Debt / EquityLower = less leverage | — | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $126.2M | ||
| Q3 25 | — | $146.6M | ||
| Q2 25 | $739.2M | $126.6M | ||
| Q1 25 | — | $129.9M | ||
| Q4 24 | $834.2M | $139.8M | ||
| Q3 24 | $422.7M | $155.8M | ||
| Q2 24 | — | $103.2M | ||
| Q1 24 | — | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | — | $541.5M | ||
| Q3 25 | — | $529.8M | ||
| Q2 25 | $778.5M | $521.1M | ||
| Q1 25 | — | $513.9M | ||
| Q4 24 | $757.5M | $505.5M | ||
| Q3 24 | $378.9M | $504.6M | ||
| Q2 24 | — | $497.7M | ||
| Q1 24 | — | $493.7M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $815.1M | $3.2B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | $864.6M | $3.0B | ||
| Q3 24 | $439.2M | $3.0B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $55.6M |
| Free Cash FlowOCF − Capex | $-37.8M | $54.6M |
| FCF MarginFCF / Revenue | -197.2% | 173.9% |
| Capex IntensityCapex / Revenue | 0.5% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $55.6M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | $-37.7M | $6.2M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | $-37.5M | $7.2M | ||
| Q3 24 | $-12.5M | $-14.6M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $1.5M |
| Q4 25 | — | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | $-37.8M | $5.9M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | $-37.5M | $4.5M | ||
| Q3 24 | $-12.6M | $-15.0M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-315.0K |
| Q4 25 | — | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | -197.2% | 22.4% | ||
| Q1 25 | — | 52.6% | ||
| Q4 24 | -293.5% | 19.7% | ||
| Q3 24 | -43.2% | -74.1% | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -1.5% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 0.5% | 1.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 0.0% | 11.9% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.20× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
